Interpace Biosciences (IDXG) investor relations material

Executive summary

• Q3 2025 revenue was $8.8M, down 29% year-over-year, primarily due to the loss of Medicare coverage for PancraGEN® and subsequent discontinuation, but with record thyroid test volumes and cash collections of $10.0M.

• Net income for Q3 2025 was $0.9M, compared to $1.7M in Q3 2024; for the nine months ended September 30, 2025, net income was $1.9M, down from $4.8M in the prior year period.

• The company transitioned to a thyroid-only diagnostics business, focusing on ThyGeNEXT and ThyraMIRv2 platforms.

• A restructuring plan was implemented in response to the loss of PancraGEN® coverage, resulting in workforce reductions and $0.7M in severance and related costs.

• Strategic investments in laboratory efficiency, AI, and automation supported operational improvements and additional principal payments on long-term debt.

Financial highlights

• Gross profit for Q3 2025 was $5.4M (62% margin), down from $7.9M (64% margin) in Q3 2024, but up from $7.3M pro forma (57% margin, excluding PancraGEN).

• Operating income from continuing operations for Q3 2025 was $1.1M, compared to $2.3M in Q3 2024 and a $0.1M loss pro forma.

• Adjusted EBITDA for Q3 2025 was $1.3M, down from $2.5M in Q3 2024, but up from $0.1M pro forma; for the nine months ended September 30, 2025, Adjusted EBITDA was $3.7M, down from $6.5M in the prior year period.

• Cash and cash equivalents as of September 30, 2025 were $1.4M; as of November 7, 2025, cash was approximately $2.1M.

• Q3 cash collections totaled $10.0M, compared to $11.2M in Q3 2024 and $7.5M pro forma.

Outlook and guidance

• Management anticipates that current cash and forecasted receipts will be sufficient to meet anticipated cash requirements for the next twelve months.

• The company continues to explore strategic alternatives and funding options due to capital market constraints following delisting from Nasdaq.

• Management expressed confidence in continued growth in revenue, profitability, and cash flow as a thyroid-only diagnostics business.

• Ongoing focus on reimbursement improvements and operational efficiency expected to support future performance.